19357-45-0

Basic information

• Product Name: 17,21-dihydroxypregn-4-ene-3,20-dione 17-acetate
• Synonyms: 17,21-dihydroxypregn-4-ene-3,20-dione 17-acetate;17,21-Dihydroxypregna-4-ene-3,20-dione 17-acetate;17-Acetyloxy-21-hydroxypregnan-4-ene-3,20-dione;Einecs 242-991-4;(8R,9S,10R,13S,14S,17R)-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate
• CAS NO: 19357-45-0
• Molecular Formula: C₂₃H₃₂O₅
• Molecular Weight: 388.49718
• EINECS: 242-991-4
• Mol File: 19357-45-0.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 528.304°C at 760 mmHg
• Flash Point: 177.887°C
• Appearance: /
• Density: 1.209g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.558
• CAS DataBase Reference: 17,21-dihydroxypregn-4-ene-3,20-dione 17-acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 17,21-dihydroxypregn-4-ene-3,20-dione 17-acetate(19357-45-0)
• EPA Substance Registry System: 17,21-dihydroxypregn-4-ene-3,20-dione 17-acetate(19357-45-0)

Safety Data

• Hazardous Substances Data: 19357-45-0(Hazardous Substances Data)

Usage

Derivation

Synthetic steroid hormone derived from progesterone.

Common use

Progestogen in hormonal contraceptive medications and hormone replacement therapy.

Chemical structure

Pregnane backbone with hydroxyl groups at positions 17 and 21, a ketone group at position 3, and an acetate group at position 17.

Progestogenic activity

Effective in preventing ovulation, thickening cervical mucus to inhibit sperm penetration, and altering the endometrium to prevent implantation of a fertilized egg.

Pharmaceutical research

Used in pharmaceutical research for the development of new medications.

Reference standard

Utilized as a reference standard in analytical chemistry for the identification and quantification of related compounds.

Mechanism of action

Binds to progesterone receptors in target tissues, leading to the modulation of gene expression and the regulation of various physiological processes.

Side effects

Potential side effects may include headaches, breast tenderness, mood changes, and irregular bleeding, among others.

Contraindications

Not recommended for individuals with a history of blood clots, liver disease, or certain types of cancer.

Dosage

Dosage varies depending on the specific medication and the individual's medical needs, as prescribed by a healthcare professional.

InChI:InChI=1/C23H32O5/c1-14(25)28-23(20(27)13-24)11-8-19-17-5-4-15-12-16(26)6-9-21(15,2)18(17)7-10-22(19,23)3/h12,17-19,24H,4-11,13H2,1-3H3/t17-,18+,19+,21+,22+,23+/m1/s1

Upstream product

• 1807-15-4 17,21-diacetoxy-4-pregnene-3,20-dione 

Downstream Products

• 2394-23-2 19,21-dihydroxypregn-4-ene-3,20-dione 
• 50-23-7 HYDROCORTISONE 
• 510-65-6 19-hydroxycortodoxone 
• 510-64-5 19-hydroxy-4-androstene-3,17-dione 
• 640-87-9 cortexolone 21-acetate 
• 16463-74-4 Cortisol-17α-monoacetat 
• 16463-74-4 Acetic acid (10R,11R,13S,17R)-11-hydroxy-17-(2-hydroxy-acetyl)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester 
• 104806-61-3 Acetic acid (10R,13S,14R,17R)-14-hydroxy-17-(2-hydroxy-acetyl)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester 

Relevant articles and documents

Lipase-catalyzed preparation of corticosteroid 17α-esters endowed with antiandrogenic activity

Several 17α-monoesters of cortexolone and its Δ9-derivative are endowed with antiandrogenic activity. Their synthesis can be accomplished by means of a lipase-catalyzed chemoselective alcoholysis of the corresponding 17α,21-diesters.